43rd week of 2010 patent applcation highlights part 45 |
Patent application number | Title | Published |
20100273641 | Self-Limiting Catalyst Composition with Non-Phthalate Internal Donor - A catalyst composition for the polymerization of propylene is provided. The catalyst composition includes one or more Ziegler-Natta procatalyst compositions having one or more transition metal compounds and an internal electron donor, one or more aluminum containing cocatalysts, and an external electron donor. The internal electron donor is a bidentate compound excluding plithalates. Suitable bidentale compounds include diethers, succinates, dialkoxybenzenes and diol esters. The external electron donor is a mixture of an activity limiting agent and selectivity determining agent. The present catalyst composition has high catalyst activity and high stereoselectivity, and is self-extinguishing. | 2010-10-28 |
20100273642 | PREPARATION OF SURFACE FUNCTIONALIZED POROUS ORGANIC-INORGANIC HYBRID MATERIALS OR MESOPOROUS MATERIALS WITH COORDINATIVELY UNSATURATED METAL SITES AND CATALYTIC APPLICATIONS THEREOF - Disclosed herein is a method of surface-functionalizing a porous organic-inorganic hybrid material or a organic-inorganic mesoporous material, in which organic substances, inorganic substances, ionic liquids and organic-inorganic hybrid substances are selectively functionalized on the coordinatively unsaturated metal sites of a porous organic-inorganic hybrid material or organic-inorganic mesoporous material, and thus the porous organic-inorganic hybrid material can be used for adsorbents, gas storage devices, sensors, membranes, functional thin films, catalysts, catalytic supports, and the like, and the applications of the surface-functionalized porous organic-inorganic hybrid material prepared using the method to catalytic reactions. | 2010-10-28 |
20100273643 | SYSTEM AND METHOD FOR PROTECTION OF SCR CATALYST AND CONTROL OF MULTIPLE EMISSIONS - The present invention relates generally to the field of emission control equipment for boilers, heaters, kilns, or other flue gas-, or combustion gas-, generating devices (e.g., those located at power plants, processing plants, etc.) and, in particular to a new and useful method and apparatus for preventing the poisoning and/or contamination of an SCR catalyst. In another embodiment, the method and apparatus of the present invention is designed to protect an SCR catalyst, while simultaneously providing emission control. | 2010-10-28 |
20100273644 | DOPED Pd/Au SHELL CATALYST, METHOD FOR PRODUCING THE SAME AND USE THEREOF - A shell catalyst for producing vinyl acetate monomer (VAM), comprising an oxidic porous catalyst support, formed as a shaped body, with an outer shell in which metallic Pd and Au are contained. To provide a shell catalyst for producing VAM which has a relatively high activity and can be obtained at relatively low cost, the catalyst support is doped with at least one oxide of an element selected from the group consisting of Li, P, Ca, V, Cr, Mn, Fe, Sr, Nb, Ta, W, La and the rare-earth metals. | 2010-10-28 |
20100273645 | Functional Surface Catalyst Composition - A catalyst composition, useful for a diversity of chemical production processes, preferably comprises a glass substrate, with one or more functional surface active constituents integrated on and/or in the substrate surface. A substantially nonporous substrate has (i) a total surface area between about 0.01 m | 2010-10-28 |
20100273646 | PURIFYING CATALYST - A purifying catalyst includes catalyst powder composed of a transition metal oxide of which an average particle diameter is within 1 nm to 2 μm and in which an electron binding energy of oxygen is shifted to an energy side lower than 531.3 eV. The purifying catalyst shows good purification performance even when noble metal is not contained as an essential component. | 2010-10-28 |
20100273647 | WATER-ABSORBING RESIN SUITABLE FOR ABSORBING VISCOUS LIQUIDS CONTAINING HIGH-MOLECULAR COMPOUND, AND ABSORBENT AND ABSORBENT ARTICLE EACH COMPRISING THE SAME - A water-absorbent resin is provided which is suitable for absorbing polymer-containing viscous liquids, wherein the specific surface area measured by the BET multipoint technique using krypton gas as the adsorption gas is no less than 0.05 m | 2010-10-28 |
20100273648 | Synergistic Fungicidal Active Substance Combinations - The novel active compound combinations of a carboxamide of the general formula (I) (group 1) | 2010-10-28 |
20100273649 | Fungicidal Mixtures III - The present invention relates to mixtures of fungicidally active compounds comprising at least one substituted 2-[hydroxyl(pyridine-3-yl)methyl]acrylate compound of the formula I | 2010-10-28 |
20100273650 | Fungicidal Mixtures Comprising a Substituted 3-Hydroxymethylpyridine and a Further Fungicidal Compound - The present invention relates to mixtures of fungicidally active compounds comprising at least one substituted 3-hydroxymethylpyridin compound formula I and at least one further fungicidally active compound II. | 2010-10-28 |
20100273651 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same - The present invention relates to azolylmethyloxiranes of the formula I | 2010-10-28 |
20100273652 | Use of 4-Aza Indole Derivatives for the Reduction of Mycotoxin Contamination - The present invention relates to a method of the reduction of mycotoxin contamination of plants and/or plant material and/or plant propagation material comprising applying to the plant or plant propagation material a effective amount of a compound of formula (I) | 2010-10-28 |
20100273653 | Use of Compounds Having a Mongalactosydiacylglycerol Syhnthase Inhibitory Activity as Herbicide or Algaecide, Herbicide and Algaecide Compositions - The invention relates to the use of compounds having a monogalactosyldiacylglycerol (MGDG) synthase inhibitory activity as herbicide or algaecide, and to herbicide and algaecide compositions containing at least one of these compounds. | 2010-10-28 |
20100273654 | HIGH-STRENGTH, HERBICIDAL COMPOSITIONS OF GLYPHOSATE AND 2,4-D SALTS - The mixture of certain amine salts of glyphosate and 2,4-D allows the preparation of high-strength liquid compositions containing up to greater than 450 gae/L of total active ingredient loading if the pH is adjusted to about 6.0 to about 8.0. Compositions are particularly well-suited for application to crops that are resistant or tolerant to both glyphosate and 2,4-D. | 2010-10-28 |
20100273655 | Composition and method for controlling invasive aquatic flora - A herbicidal blend having from a) about 0.3 to about 4 parts by volume of a herbicide; b) from about 5 to about 20 parts by volume of a modified plant oil; and c) from about 5 to about 20 parts by volume of a compostable organic particulate. A method for preparing the herbicidal blend and a method of using the blend is also disclosed. The herbicidal blend is effective in controlling invasive water plant flora such as duckweed, watermeal and parrotfeather. | 2010-10-28 |
20100273656 | COMPOSITION AND METHOD FOR SELECTIVE HERBICIDE - An environmentally safe selective herbicide is provided that includes at least one metal component and at least one chelating agent. The metal component can have a variety of forms, but is preferably in the form of a metal salt, a metal chelate, or combinations thereof The chelating agent can also have a variety of forms, but is preferably in the form of a metal chelate, a salt, an acid, or combinations thereof Methods of use are also provided. In another embodiment, an improved selective herbicide, as well of methods of controlling unwanted plants using such a herbicide, are provided. A method for treating undesired vegetation can include providing a selective herbicidal composition that includes a water-soluble selective auxin-type herbicide and a chelating agent complexed with at least one transition metal, and contacting vegetation with a herbicidally effective amount of the composition such that unwanted vegetation is controlled, while desired vegetation is unaffected. | 2010-10-28 |
20100273657 | SUPERCONDUCTING STRUCTURE FOR A FAULT CURRENT-LIMITER - A superconducting article and method of fabrication are provided. The superconducting article includes a superconducting structure, which includes a superconducting conductor and multiple discrete overlay regions of higher heat capacity than the superconducting conductor. The multiple discrete overlay regions are disposed along a length of the superconducting conductor, in thermal contact with the superconducting conductor, and positioned to define a heat modulation pattern along the length of the superconducting structure. The multiple discrete overlay regions create a temperature distribution favorable to transition of the superconducting structure under load from a normal resistive state to a superconductive state by facilitating formation of a continuous superconducting path along the length of the superconducting structure. In one implementation, the multiple discrete overlay regions are multiple island regions periodically disposed adjacent to opposing first and second edges of the superconducting conductor along the length of the superconducting conductor. | 2010-10-28 |
20100273658 | Methods for Assaying Gene Imprinting and Methylated CpG Islands - Genomic imprinting is a parent of origin-dependent gene silencing that involves marking of alleles in the germline and differential expression in somatic cells of the offspring. Imprinted genes and abnormal imprinting have been implicated in development, human disease, and embryonic stem cell transplantation. We have established a model system for genomic imprinting using pluripotent 8.5 d.p.c. mouse embryonic germ (EG) cell lines derived from an interspecific cross. We find that allele-specific imprinted gene expression has been lost in these cells. However, partial restoration of allele-specific silencing can occur for some imprinted genes after in vitro differentiation of EG cells into somatic cell lineages, indicating the presence of a gametic memory that is separable from allele-specific gene silencing. We have also generated a library containing most methylated CpG islands. A subset of these clones was analyzed and revealed a subdivision of methylated CpG islands into 4 distinct subtypes: CpG islands belonging to high copy number repeat families; unique CpG islands methylated in all tissues; unique methylated CpG islands that are unmethylated in the paternal germline; and unique CpG islands methylated in tumors. This approach identifies a methylome of methylated CpG islands throughout the genome. | 2010-10-28 |
20100273659 | Nitrilases, Nucleic Acids Encoding Them and Methods for Making and Using Them - The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature. | 2010-10-28 |
20100273660 | ONCOGENOMICS-BASED RNAi SCREEN AND USE THEREOF TO IDENTIFY NOVEL TUMOR SUPPRESSORS - In some aspects, the invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal. | 2010-10-28 |
20100273661 | Methods and Kits for Predicting Treatment Response in Type II Diabetes Mellitus Patients - A method for predicting treatment response of a type II diabetes patient to rosiglitazone is provided. The method involves at least one sample from a patient having type II diabetes and analyzing biomarkers predictive of a patient who will respond to treatment with rosiglitazone. The biomarkers include, at least, interleukin-8, histidine, citrate. These biomarkers are identified in at least one classification analyses selected from the group consisting of a majority-vote based classifier and support-vector machine (SVM) classifier. Also provided is a method for predicting treatment response of a type II diabetes patient to glyburide at 8 weeks post-initiation of therapy. The method involves obtaining a sample from a type II diabetes patient who has been treated with glyburide for about 4 weeks and analyzing biomarkers predictive of a patient who will respond to treatment with glyburide at 8 weeks. The biomarkers useful in this method include, at least, sphingomyelin 23:1 and L-phenylalanine. Also provided are kits useful for the methods of the invention. | 2010-10-28 |
20100273662 | Method of preparing libraries of template polynucleotides - The present invention relates to a method for preparing a library of template polynucleotides and use thereof in methods of solid-phase nucleic acid amplification. More specifically, the invention relates to a method for preparing a library of template polynucleotides that have common sequences at their 5′ ends and at their 3′ ends. | 2010-10-28 |
20100273663 | Methods and compositions related to arrhythmogenic right ventricular cardiomyopathy (ARVC) - This disclosure provides the identification of an eight base pair deletion in the 3′-untranslated region (UTR) of the striatin gene that is linked to arrhythmogenic right ventricular cardiomyopathy (ARVC) in Boxer dogs. Also provided are methods for detecting ARVC, methods of breeding Boxer dogs to reduce the prevalence or frequency of ARVC in a population, and methods of screening for a compound useful for treatment of ARVC. | 2010-10-28 |
20100273664 | Method For The Determination Of Intra- And Intermolecular Interactions In Aqueous Solution - The present invention relates to the determination of intra- or intermolecular interaction between molecules in aqueous solution, said method comprising the steps of: (a) determining the dehydration (ΔG | 2010-10-28 |
20100273665 | CHEMICAL SENSORS BASED ON CUBIC NANOPARTICLES CAPPED WITH AN ORGANIC COATING - The present invention provides a sensor apparatus based on 2D films or 3D assemblies of cubic nanoparticles capped with an organic coating. The apparatus is used to determine the composition and preferably measure the concentration of volatile and non-volatile compounds in a sample, with very high sensitivity. Methods for use of the apparatus in applications such as diagnosis of disease, food quality and environmental control are disclosed. | 2010-10-28 |
20100273666 | METHODS OF ANALYZING WOUND SAMPLES - A method of analyzing wound samples is provided. The analysis typically involves the use of mass spectrometry. | 2010-10-28 |
20100273667 | Cell culture well-plates having inverted colloidal crystal scaffolds - A three dimensional inverted colloidal crystal scaffold is described which comprises a substrate having at least one well. The scaffold also includes a three dimensional matrix comprising a transparent biocompatible polymeric network containing microspherical voids. The microspherical voids are each connected to at least one other void through inter-connecting pores. Additionally, an apparatus for producing such a colloidal crystal scaffold is described. Methods for making the inverted colloidal crystal scaffold, for using the scaffold and for identifying the effects of a drug, pharmaceutical or toxin on a living cell using the inverted colloidal crystal scaffold are also disclosed. | 2010-10-28 |
20100273668 | USE OF AN ENDOPLASMIN FRAGMENT AND DERIVATIVES THEREOF AS BIOMARKER FOR COLORECTAL ADENOMA AND/OR CARCINOMA; METHOD FOR DETECTION AND TEST SYSTEM - The present invention is directed to a method for detecting colorectal adenoma and/or colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of an endoplasmin fragment or a derivative thereof in said isolated sample material, c) comparing the determined level of an endoplasmin fragment or a derivative thereof with one or more reference values. The invention is further directed to a method for discriminating between colorectal adenoma and colorectal carcinoma as well as to a method for monitoring the development and/or course of colorectal adenoma and/or colorectal carcinoma and/or the treatment of colorectal adenoma and/or colorectal carcinoma. Moreover, the invention is directed to a test system and an array for use in these methods. Furthermore, the invention is directed to the use of an endoplasmin fragment as a biomarker for a detection of colorectal adenoma and/or colorectal carcinoma in an individual. Further, the invention is directed to a method for determining the effectiveness of a compound in the treatment colorectal adenoma and/or colorectal carcinoma. | 2010-10-28 |
20100273669 | METHOD FOR SELECTING A PEPTIDE OR POLYPEPTIDE WHICH BINDS TO A TARGET - A method for selecting a peptide or polypeptide which binds to a target is provided. The method is based on protein splicing and phage display. | 2010-10-28 |
20100273670 | DETECTION OF ANTIVIRAL RESISTANCE IN INFLUENZA A USING DNA MICROARRAY - Embodiments of the present invention relate to compositions, methods and apparatus for detection of antiviral agent resistance or sensitivity of a virus. In some embodiments, antiviral agent resistance or sensitivity of influenza types, such as A, B and C may be identified. In more embodiments, sub-types such as the hemagglutinin (HA) and neuraminidase (NA) of influenza A may be analyzed for antiviral agent resistance or sensitivity. In a particular embodiment, the various strains of influenza virus may be analyzed for resistance or sensitivity using DNA microarray analysis designed to target a gene segment. In various embodiments, a microarray-based assay system with capture and detection (label) probes may be utilized to identify a change in a gene segment that confers resistance or sensitivity to an antiviral agent of an influenza strain. | 2010-10-28 |
20100273671 | METHOD FOR THE DETERMINATION AND THE CLASSIFICATION OF RHEUMATIC CONDITIONS - Methods for the determination and the classification of a rheumatic condition in a synovial sample of a subject afflicted with a rheumatic condition are disclosed. Methods include the steps of determining in the level of expression of at least 20 genes or gene fragments in the synovial sample and identifying whether the level of expression of the genes in the sample correlates with the presence of a rheumatic condition. Kits are also described for the determination and the classification of rheumatic conditions which contain a low density microarray having probes suitable for hybridizing with at least 20 genes or gene fragments. On the basis of the hybridization results, the rheumatic condition is determined. | 2010-10-28 |
20100273672 | METHOD AND DEVICE FOR HIGH SENSITIVITY AND QUANTITATIVE DETECTION OF CHEMICAL/BIOLOGICAL MOLECULES - A sensor for detecting the presence of predetermined chemical/biological molecules, the sensor having a MOSFET device ( | 2010-10-28 |
20100273673 | THE METHODS FOR DETECTING MOLECULAR INTERACTIONS - The present invention relates to methods for dynamically detecting the interactions between various materials including bioactive molecules and for detecting target molecules. More specifically, the present invention relates to a method for dynamically detecting bait-prey interactions and a method for easily detecting target molecules which blocks or activates the interactions, the method comprising: allowing a material capable of forming a nano-assembly matrix, a bait and a prey to interact with each other, and analyzing whether a nano-assembly matrix is formed by the interaction between the bait and the prey in vitro or in vivo; or allowing a material capable of forming a nano-assembly matrix, a bait and a prey to interact with each other, inducing the formation of a nano-assembly matrix by a mediator (regulator) material in vitro or in vivo, and then analyzing whether the prey and the bait co-localizes on the nano-assembly matrix. | 2010-10-28 |
20100273674 | METHOD FOR THE ANALYSIS OF OVARIAN CANCER DISORDERS - The invention relates to a method for the analysis of ovarian cancer disorders, comprising determining the genomic methylation status of one or more CpG dinucleotides in a sequence selected from the group of sequences according to SEQ ID NO. 1 to 10 and/or SEQ ID NO. 50 to SEQ ID NO. 60. Optionally, additionally following steps are performed, the one or more results from the methylation status test is input into a classifier that is obtained from a Diagnostic Multi Variate Model, calculating a likelihood as to whether the sample is from a normal tissue or an ovarian cancer tissue and/or, calculating an associated p-value for the confidence in the prediction. | 2010-10-28 |
20100273675 | Methods for detecting fetal abnormality - The invention relates to a method of identifying fetal abnormality from a maternal blood sample by capturing an image of a fetal nucleated red blood cell obtained from the maternal blood sample; inputting probe intensities for a plurality of nucleic acid probes that bind fetal nucleic acids of interest; analyzing the probe intensities; and generating a diagnostic output according to results of the analysis. In some embodiments, the probes are specific to a chromosome. | 2010-10-28 |
20100273676 | HIGH THROUGHPUT SCREENS FOR SMALL-MOLECULE INHIBITORS OF THE NUCLEAR RECEPTOR-LIKE PATHWAY REGULATING MULTIDRUG RESISTANCE IN FUNGI - The present invention relates to the identification of molecular mechanisms associated with multidrug resistance (MDR) in fungal infections. More specifically, fungi harbor a nuclear receptor-like pathway controlling MDR, which represents a novel therapeutic target for the treatment of MDR in pathogenic fungi such as | 2010-10-28 |
20100273677 | PROTEIN ANALYSIS - A method of analysing the interaction between a mixture of molecular components and a group of binding agents includes the following steps. (i) Separating the molecular components in the mixture into a plurality of fractions on the basis of a physical parameter. (ii) Providing a plurality of different binding agents. (iii) Contacting the binding agents with at least two of the fractions and detecting the binding of the molecular components in each fraction to the binding agents. (iv) Detecting the presence of a plurality of the molecular components by the binding of the molecular components to the binding agents. | 2010-10-28 |
20100273678 | METHOD AND KIT TO PERFORM A PCR AMPLIFICATION AND MICRO-ARRAY DETECTION IN THE SAME MEDIUM AND/OR SAME CHAMBER - An amplification and micro-array detection method is performed in a same buffer and/or in a same reaction chamber. A kit for an amplification of multiple nucleotide targets, uses low primer concentration. | 2010-10-28 |
20100273679 | METHODS FOR THE PREPARATION OF DNA MICROARRAYS WITH LINEAR HIGH DENSITY PROBES - A method for the realisation of DNA microarrays with linear high density probes, comprising a phase of replication of template DNA strands of a template microarray and a subsequent phase of stamping of the molecules obtained by replication on a substrate via the SuNS technique; the template strands ( | 2010-10-28 |
20100273680 | METHOD AND SYSTEM FOR THE ANALYSIS OF HIGH DENSITY CELLS SAMPLES - Methods for forming cell arrays of multiple cell samples arranged substantially in a monolayer on a single substrate particularly suited for diagnostic analysis are disclosed. The cell arrays are formed with a high-speed dispensing apparatus capable of dispensing small volumes in precise, complex patterns. Also disclosed are substrates upon which cell arrays may be formed, and methods for conducting diagnostic analyses on the formed cell arrays. | 2010-10-28 |
20100273681 | COMBINATORIAL CHEMISTRY REACTION CELL WITH OPTICAL TWEEZERS - Methods for synthesizing chain molecules on particles in a multi-stream laminar flow, microfluidic reaction cells in which the methods can be carried out, and microfluidic systems incorporating the microfluidic reaction cells are provided. The methods, cells and systems are well suited for the rapid, large-scale production of chain biomolecules, such as oligonucleotides, in parallel. | 2010-10-28 |
20100273682 | WELL TREATMENT - The present invention provides a method for increasing the retention of a scale inhibitor within a hydrocarbon producing system (e.g. a subterranean formation), said method comprising contacting said system with a polymer foamed from a diallyl ammonium salt and with said scale inhibitor, wherein said polymer formed from a diallyl ammonium salt has a molecular weight of greater than 50,000 (e.g. a molecular weight of 55,000 to 2,000,000). | 2010-10-28 |
20100273683 | Compositions having hase rheology modifiers - A monomer compound that contains at least one polymerizable functional group per molecule, and at least one bicycloheptyl-, bicycloheptenyl-, or branched (C | 2010-10-28 |
20100273684 | Method for enhancing stability of oil based drilling fluids at high temperatures - Methods for enhancing the stability of ester based drilling fluids for drilling, running casing in, and/or cementing a borehole in a subterranean formation are disclosed, as well as improved ester based drilling fluids for use at high temperatures. The advantages of the invention are realized by inhibiting hydrolysis of the esters in the drilling fluid by adding a monomeric or polymeric carbodiimide hydrolysis inhibitor to the drilling fluid. | 2010-10-28 |
20100273685 | Methods and composition relating to the chemical degradation of degradable polymers - Methods comprising: providing a degradable polymer within a portion of a subterranean formation; introducing a base solution into the portion of the subterranean formation, wherein the base solution comprises at least one base selected from the group consisting of: ammonium hydroxide, an alcoholic alkaline solution, and an alkaline amine solution, and derivatives thereof; and allowing the base solution to degrade the degradable polymer. | 2010-10-28 |
20100273686 | MOLDING MATERIAL FOR BEARING, BEARING AND SUBMERSIBLE PUMP - An object of the present invention is to provide a molding material for bearing that is excellent in moldability, that does not cause the problem of SOx generation, that has high slidability and excellent abrasion resistance, and that provides a bearing having chemical resistance and heat resistance that are equal to or higher than those of a bearing formed with polyphenylene sulfide; a bearing produced with the molding material for bearing and used for a pump; and a submersible pump including the bearing. | 2010-10-28 |
20100273687 | Universal Synthetic Lubricant, Method and Product-by-Process to Replace the Lost Sulfur Lubrication when Using Low-Sulfur Diesel Fuels - A diesel fuel lubricant as a replacement for sulfur lubrication in Ultra-Low and Low Sulfur Diesel fuels, the process for producing said lubricant, and the method of using said lubricant. This lubricant comprises alpha-olefins; low odor aromatic solvents; and at least one a base oil selected from the base oil group consisting of hydrolsomerized high base oils and HT Severe Hydro-cracked Base Oils; as well as other ingredients. Also disclosed is a method for producing this lubricant. | 2010-10-28 |
20100273688 | Universal Synthetic Penetrating Lubricant, Method and Product-by-Process - A penetrating lubricant with the capacity to offer a both penetration into rust and corrosion. Further, this lubricant actively penetrates the crystalline surface of the metal while exhibiting extreme pressure lubrication, non-migrating with lasting protection. Further lubricant exhibits dielectric strength of over 8000 volts, at the same time cleaning electrical contacts, thereby reducing resistance and associated heat. The preferred embodiment contains alpha-olefins, low-odor aromatic solvents, base oils, and high flash mineral spirits. | 2010-10-28 |
20100273689 | LITHIUM HYDROXIDE COMPOSITION, A PROCESS FOR PREPARING A LITHIUM HYDROXIDE COMPOSITION, AND A PROCESS FOR USING A LITHIUM HYDROXIDE COMPOSITION - The invention provides for a lithium hydroxide composition including lithium hydroxide, a base oil, and a fatty acid salt. The invention also provides for a process for preparing a lithium hydroxide composition including contacting a lithium hydroxide component, a base oil, and a fatty acid component. The invention also provides for a process of using a lithium hydroxide composition for preparing a soap concentrate or a grease. | 2010-10-28 |
20100273690 | Synergistic combination of demulsifiers for enhancing demulsification properties in industrial lubricants - A synergistic demulsifier composition for the improvement of demulsification properties and method of making said composition is disclosed along with a lubricant composition containing same. The demulsifier composition consists of effective amounts of one or more demulsifier additives and one or more dispersants. The demulsifier additives consist of a first copolymer of propylene oxide and ethylene oxide and a second copolymer of propylene oxide and ethylene oxide. The dispersant can be an untreated polyalkene succinimide type dispersant, preferably an untreated polyisobutylene succinimide type dispersant. | 2010-10-28 |
20100273691 | Method for improving the corrosion inhibiting properties of lubricant compositions - Lubricating oils of improved initial and long term metal corrosion inhibiting properties comprises a base stock containing one or more hydrodewaxate or hydroisomerate base stock(s) and/or base oil(s), GTL base stock(s) and/or base oil(s), or mixtures thereof, preferably GTL base stock(s) and/or base oil(s), boiling in the lubricating oil boiling range and an additive amount of an anti-corrosion additive. | 2010-10-28 |
20100273692 | Ethylene-Based Copolymers, Lubricating Oil Compositions Containing the Same, and Methods for Making Them - Provided are ethylene-based copolymers, methods of preparing the same, lubricating oil compositions including the same, methods for preparing such lubricating oil compositions, and end uses for such ethylene-based copolymers and lubricating oil compositions. The ethylene-based copolymers may include less than about 80 wt. % of units derived from ethylene and one or more alpha-olefin comonomers having 3 to 20 carbon atoms. The ethylene-based copolymers have a melting peak (Tm), as measured by DSC, of 80° C. or less, and a polydispersity index of about 2.8 or less. In some embodiments, the ethylene-based copolymers have an intramolecular composition distribution of about 50 wt. % or less and/or an intermolecular composition distribution of about 50 wt. % or less. | 2010-10-28 |
20100273693 | Polymeric Compositions Useful as Rheology Modifiers and Methods for Making Such Compositions - Disclosed are rheology modifiers comprising compositionally disperse polymeric compositions and/or crystallinity disperse polymeric compositions that may be useful in modifying the rheological properties of lubrication fluids, and methods for making such compositions. The compositionally disperse polymeric composition are formed from at least two discrete compositions of ethylene copolymers. The crystallinity disperse polymeric composition are formed from ethylene copolymers having at least two discrete values of residual crystallinity. | 2010-10-28 |
20100273694 | SURFACTANT COMPOSITION METHOD FOR PRODUCTION THEREOF AND COSMETIC COMPRISING SAID COMPOSITION - The invention relates to surfactant compositions made from esters or amides of the betaine glycine, produced by reaction of the glycine betaine with a sulphonic acid and an alcohol or a fatty-chain amine derived from vegetable oils. The invention further relates to a cosmetic comprising said surfactant composition, in particular, liquid soap, bath foam, shower gel or shampoo. | 2010-10-28 |
20100273695 | Ink cleaning composition and methods for use - An environmentally-friendly cleaning composition for industrial and consumer applications comprising (a) a blend of dibasic esters, (b) one or more surfactants (c) and, optionally, (d) water or a solvent. The dibasic esters are be derived from a blend of adipic, glutaric, and succinic diacids, and, in one particular embodiment, the blend comprises dialkyl adipate, dialkyl methylglutarate and dialkyl ethylsuccinate, wherein the alkyl groups individually comprise a C | 2010-10-28 |
20100273696 | Composition and method for the prevention and removal of unwanted paint on a surface - An environmentally safe formulation to prepare an effective and permanent protection layer on almost all surfaces. The formulation consists of a combination of different silicon organic compounds, namely [a] end standing mono-, di- or tris-amino-alkyl-alkoxysilanes and [b] mono-, di-, or tris-alkyl-amino-alkylsilanes, in a long-chained isoparaffinic solution. The silicon organic compounds starts to polymerize in the presence of oxygen (air) and/or water (humidity), and builds up a net structure that water molecules can penetrate through the cured protective layer. Depending on the types of the silicon organic compounds, the pore width of the net structure can be verified. It is also possible to remove this protection layer, by using a special water based mixture of hydrofluoric acid and an inert surfactant. | 2010-10-28 |
20100273697 | COPOLYMER FOR PROCESSING OR MODIFYING SURFACES - The invention relates to a composition for processing and/or modifying surfaces, in particular hard surfaces. The composition includes a synthetic copolymer that comprises cationic units and units derived from a vinyl-lactam. | 2010-10-28 |
20100273698 | Compositions - A process for the preparation of a package containing a compacted particulate composition, comprises wrapping a compacted particulate composition to sealing same with at least one film. Thereafter treating the resultant seams of the sealed composition to produce a package that is suitable for handling by a user than known packages. | 2010-10-28 |
20100273699 | USE OF HOMOPOLYMERS OF MALEIC ACID AND ITS SALTS AS SCALE-INHIBITING AGENTS AND ANTI-STICK AGENTS - The invention consists of the use, as scale-prevention and sticking-prevention agents, of homopolymers derived from a maleic acid polymerization, in the presence of a catalytic system using oxygenated water and sodium hypophosphite, in which the molar ratio of sodium hypophosphite/maleic acid is between 0.2 and 1, and preferentially between 0.35 and 0.6. | 2010-10-28 |
20100273700 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-10-28 |
20100273701 | USE OF SALUSIN BETA ALONE OR IN COMBINATION WITH OCTREOTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ala-lle-Phe-lle-Phe-lle-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-lle-Phe-lle-Phe-lle-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-10-28 |
20100273702 | CHIMERICAL PEPTIDIC MOLECULES WITH ANTIVIRAL PROPERTIES AGAINST THE VIRUSES OF THE FLAVIVIRIDAE FAMILY - The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family. | 2010-10-28 |
20100273703 | Co-Therapy For Diabetic Conditions - Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof. Drug products including a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof, in combination are also disclosed. | 2010-10-28 |
20100273704 | METHODS OF MODULATING CELLULAR HOMEOSTATIC PATHWAYS AND CELLULAR SURVIVAL - The invention provides composition and therapeutic, methods for modulating homeostatic pathways that are useful in treatment, and prevention of diabetes, diabetes associated disorders, metabolic disorders and cancer. | 2010-10-28 |
20100273705 | Method for inhibiting "Melanoma Inhibitory Activity" MIA - The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA). | 2010-10-28 |
20100273706 | Injectable Calcium Phosphate Solid Rods and Pastes for Delivery of Osteogenic Proteins - Osteogenic proteins are delivered via an injectable solid rod or hardenable paste. The formulation comprises a calcium phosphate material, an osteogenic protein, and optional additives and active ingredients such as a bone resorption inhibitor. Methods of making injectable pharmaceutical compositions and methods of using the osteogenic compositions to treat bone defects are also disclosed. | 2010-10-28 |
20100273707 | METHODS OF INHIBITING TUMOR CELL AGGRESSIVENESS USING THE MICROENVIRONMENT OF HUMAN EMBRYONIC STEM CELLS - The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity. | 2010-10-28 |
20100273708 | ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF - The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases. | 2010-10-28 |
20100273709 | Composition Comprising Desmopressin - The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient. It addresses means for providing increased shelf-life for said active ingredient in said dosage form. | 2010-10-28 |
20100273710 | Highly Potent Full and Partial Agonists and Antagonists of the Nociceptin/Orphanin FQ Receptor - Peptide analogs of nociceptin/orphanin FQ, compositions thereof, and their use in treatment of disorders and dysfunctions related to activation or blocking of NOP receptors are described. | 2010-10-28 |
20100273711 | INDIVIDUALIZED CANCER TREATMENTS - Provided herein are methods for the use of gene expression profiling to determine whether an individual afflicted with cancer will respond to a therapy, and in particular to therapeutic agents such as platinum-based agents and antimetabolite agents. Methods for the treatment of individuals with the therapeutic agents are also provided. Methods of predicting the efficacy of cancer therapeutic agents such as platinum-based and antimetabolite therapeutic agents are also provided. Kits including gene chips and instructions for predicting responsiveness are also provided. | 2010-10-28 |
20100273712 | SURFACTANT USAGE IN LUNG TRANSPLANTATION AND METHODS THEREOF - The present invention is directed to the use of pulmonary surfactants, and particularly pulmonary surfactants containing hydrophobic surfactant-associated proteins B, C or both (i.e., surfactants such as calfactant (Infasurf®), to treat PGD and other adverse effects of lung transplantation. | 2010-10-28 |
20100273713 | Diagnosis and Treatment of Congenital Heart Defects Using NELL1 - The present invention provides diagnostic methods for detecting congenital heart defects, or increased risk thereof, based on the Nell1 gene, RNA and protein. The methods include obtaining a biological sample and assessing the presence of a mutation in the Nell1 gene, RNA or protein. The presence of a mutation in the Nell1 gene, RNA or protein can be assessed by determining the levels of Nell1 gene, RNA or protein in the biological sample. The present invention further provides therapeutic methods for treating congenital heart defects based on the Nell1 gene, RNA and protein. | 2010-10-28 |
20100273714 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS - The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus. | 2010-10-28 |
20100273715 | USE OF A PEPTIDE AND AN ANALGESIC PHARMACEUTICAL AGENT - Inflammation caused by disease states such as rheumatism, gout, neurodegeneration and tumours result in the increased effectiveness of the opioid peptide biphalin or its analogues, due likely to the increased permeability of the “blood-brain barrier”, due to which it becomes possible to use the opioid peptide to produce a new analgesic for use during inflammation caused by rheumatism, gout, neurodegeneration, post-surgical or post-accidental trauma or tumours. | 2010-10-28 |
20100273716 | NEW USES FOR AMINO ACID ANTICONVULSANTS - The present invention is directed to the use of compounds of the formula: | 2010-10-28 |
20100273717 | Use of an Extract from the Vigna Aconitifolia Plant in a Cosmetic and/or Dermopharmaceutical Composition - An active composition for treating skin having a protein-containing extract from a | 2010-10-28 |
20100273718 | Milk Protein Hydrolyzates with Reduced Immunogenic Potential - Hydrolyzate compositions comprising at least one milk protein or whey hydrolyzed with at least one proteolytic enzyme are provided. The hydrolyzates reduce the immunogenicity of the milk or whey protein in a subject predisposed to having an immune reaction to the protein. Methods for making the compositions are also provided, as food products and nonfood products comprising the compositions. | 2010-10-28 |
20100273719 | USE OF SOMATOSTATIN ANALOGS IN MENINGIOMA - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma. | 2010-10-28 |
20100273720 | Protective Complement Proteins and Age-Related Macular Degeneration - Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including treating a subject having signs and/or symptoms of AMD or who has been diagnosed with AMD. | 2010-10-28 |
20100273721 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISORDERS - The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity. | 2010-10-28 |
20100273722 | MODIFIED MINIATURE PROTEINS - The present invention generally relates to modified miniature proteins, including modified avian pancreatic polypeptides (aPP) and modified pancreatic peptide YYs (PYY). One aspect of the invention is generally directed to various aPPs that have been modified such that they do not substantially form multimers in solution, for example through the addition of a proline switch. Another aspect of the invention is generally directed to modified PYYs, such as YY3. Yet another aspect of the invention is generally directed to composites of modified miniature proteins formed from portions of different miniature proteins such as aPP and/or PYY, optionally with a proline switch. Still other aspects of the invention are generally directed to methods of making such proteins, methods of using such proteins, kits involving such proteins, and the like. | 2010-10-28 |
20100273723 | PEPTIDES OF IL-2 - The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents. | 2010-10-28 |
20100273724 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS - This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also disclosed | 2010-10-28 |
20100273725 | Novel compounds useful in therapeutic and cosmetic methods - The present invention relates to photosensitizer compounds for use in cosmetic and therapeutic applications of photodynamic therapy. The compounds of the present invention are designed for topical application and are characterized by a low permeability to the stratum corneum (the outer skin layer of an individual) and/or a low allergenic potential. Surprisingly, such compounds have beneficial properties in the treatment of certain diseases and lack the undesired damages to healthy skin entailed by prior art compounds. ALA (5-aminolevulinic acid)-esters of body-owned, natural compound such as aminoacids, steroids, carbohydrades, alcohols are preferred, examples of photosensitizers of the present invention. The compounds of the present invention are used in the treatment of skin diseases such as psoriasis, sebaceous glands related conditions including acne, seborrhoic dermatitis, rosacea, skin cancer and precancer, as well as in cosmetic hair removal. | 2010-10-28 |
20100273726 | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACTIVE METABOLITES ISOLATED FROM LAURUS NOBILIS AND COMBINATIONS THEREOF - This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from | 2010-10-28 |
20100273727 | ORAL ADMINISTRATION COMPOSITION - A composition which has high safety and is excellent in the effect of reducing body fat, such as visceral fat, subcutaneous fat and the like, and neutral fat, and a food, a pharmaceutical and a feed comprising the same, are provided. | 2010-10-28 |
20100273728 | Formulations For The Oral Administration of Therapeutic Agents and Related Methods - The present application relates to an oral formulation of amphotericin B and other therapeutic agents, which formulation comprises one or more fatty acid glycerol esters and one or more PEG modified phospholipids or fatty acid esters. The formulation provides enhanced bioavailability and/or increased stability of the therapeutic agent at the low pH found in gastric fluid. | 2010-10-28 |
20100273729 | Compositions Comprising Compounds Of Natural Origin For Damaged Skin - The present invention relates to a skin-protecting composition for the damaged skin, comprising glycyrrhizin, quercetin, rosmarinic acid, madecassic acid, chamazulene, bicalein and emodin. The composition of the present invention has all of excellent antioxidant, anti-inflammatory, wound-healing and moisturizing effects, thereby being widely used in medicine, cosmetic material or the like for the purpose of protecting the easily infectable, damaged and dried skin. | 2010-10-28 |
20100273730 | SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS OF HYDROPHILIC DRUGS AND PREPARATION THEREOF - The present invention provides an oral self micro-emulsifying pharmaceutical composition of a hydrophilic drug or a pharmaceutically acceptable salt thereof which, in addition to the hydrophilic drug, one or more solvents for solving the hydrophilic drug to form a drug-solvent solution and a surfactant system, further comprises one or more hydrophilic carrier which are compatible with said drug-solvent solution and the surfactant system. The oral self micro-emulsifying pharmaceutical composition of the invention exhibits comparative bioavailability to that of the hydrophilic drug through injection and is stable during storage. A method for preparing the oral self micro-emulsifying pharmaceutical composition is also provided. | 2010-10-28 |
20100273731 | Medium-Chain Length Fatty Acids, Salts and Triglycerides in Combination with Gemcitabine for Treatment of Pancreatic Cancer - The present invention relates to the use of medium-chain length fatty acids of formula I, triglycerides of formula 2 (wherein n=6-10), salts thereof, or mixtures thereof, in combination with gemcitabine and optionally erlotinib in the treatment of pancreatic cancer in human patients. Exemplary medium-chain length fatty acid/triglyceride compounds include capric acid, sodium caprate, tricaprin, lauric acid, sodium laurate, and trilaurin. | 2010-10-28 |
20100273732 | COMBINATION METHODS OF TREATING CANCER - The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic. | 2010-10-28 |
20100273733 | HIV Treatment - The invention is directed to a method of treating an HIV infection comprising administering an aminoalkanol and a glucocorticoid. The invention is also directed to a pharmaceutical composition comprising the aminoalkanol and the glucocorticoid in amounts effective to selectively eliminate HIV-infected cells and/or to inhibit HIV replication. A method of enhancing the anti-HIV effect of the antiretroviral drug AZT by administering with the AZT, a pharmaceutical composition comprising an aminoalkanol and a glucocorticoid. | 2010-10-28 |
20100273734 | Derivatives of Hyaluronic Acids - The present invention relates to methods for preparing a derivative of a hyaluronic acid, comprising: (a) mixing a liquid solution comprising the hyaluronic acid and a diamine, a polyamine, or a combination thereof, at a pH suitable to form an imine; (b) reducing the imine to an amine with a reductant at a pH suitable to produce the derivative of the hyaluronic acid; and (c) recovering the derivative of the hyaluronic acid. The present invention also relates to isolated derivatives of a hyaluronic acid, comprising the hyaluronic acid and a diamine, a polyamine, or a combination thereof. | 2010-10-28 |
20100273735 | SOLUBLE, HIGHLY BRANCHED GLUCOSE POLYMERS FOR ENTERAL AND PARENTERAL NUTRITION AND FOR PERITONEAL DIALYSIS - The invention relates to soluble, highly branched glucose polymers which are obtained by enzymatic treatment of starch, having a reducing sugars content of less than 3.5%, exhibiting a proportion of α-1,6-glucosidic linkages of between 20% and 30%, a Mw, determined by light scattering, of between 20·10 | 2010-10-28 |
20100273736 | COSMETIC COMPOSITION COMPRISING GLYCOGEN FOR SKIN APPLICATION WITH VELVET EFFECT - This invention relates to a cosmetic composition for skin application having a velvet effect on the skin comprising, as the cosmetic active ingredient, a glycogen having less than 1,000 ppm of nitrogen and less than 1% by weight of reducing sugars, in at least one cosmetically-acceptable vehicle. | 2010-10-28 |
20100273737 | SUPPLEMENTARY FOOD COMPOSITION FOR REDUCING BODY ODOR - A food supplement for reducing body odor which includes a mixture of edible carriers with chitin aqueous solution lyophilized powder, chitosan aqueous solution lyophilized powder, chitin powder, chitosan powder, or a combination of these ingredients, in the form of tablets or pills. The food supplement has the outstanding effect of reducing various types of body odors, including Koreans' unique body odor, such as Kimchi smell or garlic smell; westerners' unique body odor, such as cheese smell or butter smell, Arabs' unique body odor, such as mutton smell, armpit odor and body odor that is unique to the aged. | 2010-10-28 |
20100273738 | INTEGRATED PATIENT MANAGEMENT AND CONTROL SYSTEM FOR MEDICATION DELIVERY - An integrated patient monitoring and control system is provided which includes a closed-loop control system for monitoring and adjusting the heparin infusion rate for a patient. The system includes a processor which uses a dynamic patient model that is continuously adjusted based on the patient's aPTT measurements to calculate an optimal heparin infusion rate to achieve an operator-input aPTT target range. The processor also includes a forecasting model to calculate the optimum sample time interval for measuring the patient's aPTT to calculate a new infusion rate. An automated sampling system, which includes a storage device for storing a series of assay devices, an advancement mechanism for moving the assay devices to a sample area, and a measurement device for analyzing a sample dispensed on the assay, is provided. The sampling system is used to repeatedly measure the patient's aPTT according to the sample time interval determined by the processor. | 2010-10-28 |
20100273739 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy - The present invention relates to aminotetraline derivatives of the formula (I) | 2010-10-28 |
20100273740 | Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses and Coronaviruses - Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents. | 2010-10-28 |